Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dermapharm Holding SECHIX:DMPD 80 Shiller PE Ratio is 19.99 as of Aug. 04, 2026, which is 17% above its 10-year median of 17.03. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €43.99. The stock has 5 warning signs investors should review. Among 536 Drug Manufacturers companies, Dermapharm Holding SE ranks better than 70.52% on this metric.
The historical rank and industry rank for Dermapharm Holding SE's Shiller PE Ratio or its related term are showing as below:
CHIX:DMPd'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.19 Med: 17.03 Max: 19.7
Current: 16.2
During the past years, Dermapharm Holding SE's highest Shiller PE Ratio was 19.70. The lowest was 14.19. And the median was 17.03.
CHIX:DMPd's Shiller PE Ratio is ranked better than 70.52% of 536
companies
in the Drug Manufacturers industry
Industry Median: 25.01
vs CHIX:DMPd: 16.20
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Dermapharm Holding SE's adjusted earnings per share data for the three months ended in Mar. 2026 was €0.840. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €2.31 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Dermapharm Holding SE (CHIX:DMPd) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Dermapharm Holding SE Shiller PE Ratio Related Terms
Dermapharm Holding SE Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Dermapharm Holding SE's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DMPD vs ZTS, UTHR: Shiller PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's Shiller PE Ratio falls into.
Dermapharm Holding SE Shiller PE Ratio Calculation
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Dermapharm Holding SE (CHIX:DMPD) has a Shiller PE Ratio of 19.99 as of Aug. 04, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Dermapharm Holding SE and its competitors. This is 17% above median its historical median of 17.03. Over the past decade, Dermapharm Holding SE's Shiller PE Ratio has ranged from 14.19 to 19.70. According to the industry distribution chart, Dermapharm Holding SE ranks #158 out of 536 companies in the Drug Manufacturers industry, placing it in the top 29.5%.
Is Dermapharm Holding SE's Shiller PE Ratio too high?
Dermapharm Holding SE's current Shiller PE Ratio of 19.99 is 17% above median its 10-year median of 17.03. Over the past 10 years, this metric has ranged from a low of 14.19 to a high of 19.70. The Drug Manufacturers industry median Shiller PE Ratio is 25.01. Dermapharm Holding SE's value of 19.99 is 20.1% below this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #158 out of 536 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Shiller PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #158 out of 536 companies for Shiller PE Ratio. This puts Dermapharm Holding SE in the upper half of its industry. The industry median Shiller PE Ratio is 25.01. Dermapharm Holding SE's value of 19.99 is 20.1% below this benchmark. Historically, Dermapharm Holding SE's own Shiller PE Ratio has ranged from 14.19 to 19.70 over the past decade. While the company's 10-year median is 17.03 vs. the industry median of 25.01, Dermapharm Holding SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 25.01, based on 536 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current Shiller PE Ratio of 19.99 is 20.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 25.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current Shiller PE Ratio is 19.99, which is 17% above median its own 10-year median of 17.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current Shiller PE Ratio of 19.99. The stock's GF Value™ is €43.99, compared to a current price of €46.18 — trading 5% above its estimated fair value. The current Shiller PE Ratio is 19.99, which is 17% above median its 10-year median of 17.03 and 20.1% below the Drug Manufacturers industry median of 25.01. Dermapharm Holding SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current Shiller PE Ratio is 19.99 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.18 is trading 5% above its estimated GF Value™ of €43.99.
Key valuation signals for CHIX:DMPD:
Shiller PE Ratio: 19.99 (17% above median its 10-year median of 17.03)
GF Value™: €43.99 vs. price of €46.18 (5% above fair value)
Industry Position: 20.1% below the Drug Manufacturers median (#158 of 536)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score
Get the complete analysis for CHIX:DMPD
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 
